Skip to main content
SpringerLink
Log in

Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in elderly HL: a two-center experience in 123 patients

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Elderly Hodgkin lymphoma (HL) is an aggressive lymphoma subgroup with high 18F-FDG avidity at 18F-FDG-PET/CT but no shared criteria for PET/CT in treatment evaluation and prediction of outcome are available. The aim of our bicentric study was to investigate whether the metabolic baseline PET/CT parameters can predict treatment response and prognosis in elderly HL. We retrospectively included 123 patients who underwent baseline 18F-FDG-PET/CT and end of treatment PET/CT scans. The PET images were analyzed visually and semi-quantitatively by measuring the lesion to liver SUVmax ratio (L-L SUV R), lesion to blood-pool SUVmax ratio (L-BP SUV R), metabolic tumor volume (MTV), and total lesion glycolysis (TLG). Survival curves were plotted according to the Kaplan-Meier method. At a median follow-up of 40 months, the median PFS and OS were 29 and 37 months. L-BP SUV R, L-L SUV R, MTV, and TLG were significantly higher in patients with no complete response compared with complete response group at end of treatment. Moreover, these parameters were demonstrated to be independent prognostic factors for PFS together with tumor stage, while only L-L SUV R and L-BP SUV R for OS. End of treatment PET/CT results using Deauville criteria were significantly correlated with outcome survival. End of treatment PET/CT results (using Deauville criteria) and semiquantitative baseline PET/CT parameters were significantly correlated with response to treatment and long-term outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Halbsguth TV, Böll B, Borchmann P, Diehl V (2011) The unique characteristics and management of patients over 60 years of age with classic Hodgkin lymphoma. Curr Hematol Malig Rep 6:164–171

    Article  PubMed  Google Scholar 

  2. Proctor SJ, Wilkinson J, Sieniawski M (2009) Hodgkin lymphoma in the elderly: a clinical review of treatment and outcome, past, present and future. Crit Rev Oncol Hematol 71:222–232

    Article  CAS  PubMed  Google Scholar 

  3. Evens AM, Sweetenham J.W, Horning SJ. Hodgkin lymphoma in older patients: an uncommon disease in need of study. Oncology (Williston Park, NY) 2008;22:369–379

  4. Klimm B, Diehl V, Engert A. Hodgkin’s lymphoma in the elderly: a different disease in patients over 60. Oncology (Williston Park, NY) 2007;21:982–990

  5. Prochazka V, Gawande RS, Cayci Z et al (2018) Positron emission tomography-based assessment of metabolic tumor volume predicts survival after autologous hematopoietic cell transplantation for Hodgkin lymphoma. Biol Blood Marrow Transplant 24:64–70

    Article  PubMed  Google Scholar 

  6. Moskowitz AJ, Schoder H, Gavane S et al (2017) Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. Blood. 130:2196–2203

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA, Alliance, Australasian Leukaemia and Lymphoma Group, Eastern Cooperative Oncology Group, European Mantle Cell Lymphoma Consortium, Italian Lymphoma Foundation, European Organisation for Research, Treatment of Cancer/Dutch Hemato-Oncology Group, Grupo Español de Médula Ósea, German High-Grade Lymphoma Study Group, German Hodgkin's Study Group, Japanese Lymphorra Study Group, Lymphoma Study Association, NCIC Clinical Trials Group, Nordic Lymphoma Study Group, Southwest Oncology Group, United Kingdom National Cancer Research Institute (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059–3068

    Article  PubMed  PubMed Central  Google Scholar 

  8. Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller SP, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O’Doherty MJ, Hustinx R, Biggi A, Cheson BD (2014) Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol 32:3048–3058

    Article  PubMed  PubMed Central  Google Scholar 

  9. Kostakoglu L, Chauvie S (2018) Metabolic tumour volume metrics in lymphoma. Semin Nucl Med 48:50–66

    Article  PubMed  Google Scholar 

  10. Albano D, Bosio G, Pagani C, Re A, Tucci A, Giubbini R, Bertagna F (2019) Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma. Eur J Nucl Med Mol Imaging 46:87–96

    Article  PubMed  Google Scholar 

  11. Albano D, Bertoli M, Battistotti M, Rodella C, Statuto M, Giubbini R, Bertagna F (2018) Prognostic role of pretreatment 18F-FDG PET/CT in primary brain lymphoma. Ann Nucl Med 32:532–541

    Article  CAS  PubMed  Google Scholar 

  12. Albano D, Bosio G, Bianchetti N et al (2019) Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in mantle cell lymphoma. Ann Nucl Med 33:280–287

    Article  PubMed  Google Scholar 

  13. Albano D, Bosio G, Camoni L, Farina M, Re A, Tucci A, Giubbini R, Bertagna F (2019) Prognostic role of baseline 18F-FDG PET/CT parameters in MALT lymphoma. Hematol Oncol 37:39–46

    Article  CAS  PubMed  Google Scholar 

  14. Procházka V, Klugar M, Bachanova V et al (2016) Comparing the accuracy of quantitative versus qualitative analyses of interim PET to prognosticate Hodgkin lymphoma: a systematic review protocol of diagnostic test accuracy. BMJ Open 5:6

    Google Scholar 

  15. Boellaard R, Delgado-Bolton R, Oyen WJ et al (2015) FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42:328–354

    Article  CAS  PubMed  Google Scholar 

  16. Bentur OS, Dann EJ, Paran E, Lavie D, Nachmias B, Ron Y et al (2019) Interim PET-CT-guided therapy in elderly patients with Hodgkin lymphoma-a restroispective national multi-center study. Ann Hematol. https://doi.org/10.1007/s00277-019-03686-y

  17. Thyss A, Saada E, Gastaud L, Peyrade F, Ré D (2014) Hodgkin's lymphoma in older patients: an orphan disease? Mediterr J Hematol Infect Dis 6:e2014050

    Article  PubMed  PubMed Central  Google Scholar 

  18. Jagadeesh D, Diefenbach C, Evens AM (2013) XII. Hodgkin lymphoma in older patients: challenges and opportunities to improve outcomes. Hematol Oncol 69(Suppl 1):–75

  19. Björkholm M, Weibull CE, Eloranta S, Smedby KE, Glimelius I, Dickman PW (2018) Greater attention should be paid to developing therapies for elderly patients with Hodgkin lymphoma-a population-based study from Sweden. Eur J Haematol 101:106–114

    Article  PubMed  Google Scholar 

  20. Ballova V, Ruffer JU, Haverkamp H et al (2005) A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin’s disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol 16:124–131

    Article  CAS  PubMed  Google Scholar 

  21. Evens AM, Hong F (2013) How can outcomes be improved for older patients with Hodgkin lymphoma? J Clin Oncol 31:1502–1505

    Article  PubMed  Google Scholar 

  22. Böll B, Görgen H, Fuchs M, Pluetschow A, Eich HT, Bargetzi MJ, Weidmann E, Junghanß C, Greil R, Scherpe A, Schmalz O, Eichenauer DA, von Tresckow B, Rothe A, Diehl V, Engert A, Borchmann P (2013) ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. J Clin Oncol 31:1522–1529

    Article  PubMed  Google Scholar 

  23. Evens AM, Hong F, Gordon LI, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Gospodarowicz M, Cheson BD, Stiff PJ, Advani R, Miller TP, Hoppe RT, Kahl BS, Horning SJ (2013) The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol 161:76–86

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Levis A, Anselmo AP, Ambrosetti A, Adamo F, Bertini M, Cavalieri E, Gavarotti P, Genua A, Liberati M, Pavone V, Pietrasanta D, Ricetti MM, Scalabrini DR, Salvi F, Vitolo U, Angelucci E, Boccadoro M, Gallo E, Mandelli F, Intergruppo Italiano Linfomi (IIL) Intergruppo Italiano Linfomi (IIL) (2004) VEPEMB in elderly Hodgkin’s lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. Ann Oncol 15:123–128

  25. Proctor SJ, Wilkinson J, Jones G, Watson GC, Lucraft HH, Mainou-Fowler T, Culligan D, Galloway MJ, Wood KM, McNally RJQ, James PW, Goodlad JR (2012) Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. Blood 119:6005–6015

    Article  CAS  PubMed  Google Scholar 

  26. Dührsen U, Müller S, Hertenstein B, Thomssen H, Kotzerke J, Mesters R, Berdel WE, Franzius C, Kroschinsky F, Weckesser M, Kofahl-Krause D, Bengel FM, Dürig J, Matschke J, Schmitz C, Pöppel T, Ose C, Brinkmann M, la Rosée P, Freesmeyer M, Hertel A, Höffkes HG, Behringer D, Prange-Krex G, Wilop S, Krohn T, Holzinger J, Griesshammer M, Giagounidis A, Raghavachar A, Maschmeyer G, Brink I, Bernhard H, Haberkorn U, Gaska T, Kurch L, van Assema DME, Klapper W, Hoelzer D, Geworski L, Jöckel KH, Scherag A, Bockisch A, Rekowski J, Hüttmann A, on behalf of the PETAL Trial Investigators (2018) Positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial. J Clin Oncol 36:2024–2034

    Article  PubMed  Google Scholar 

  27. Kanoun S, Rossi C, Berriolo-Riedinger A, Dygai-Cochet I, Cochet A, Humbert O, Toubeau M, Ferrant E, Brunotte F, Casasnovas RO (2014) Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 41:1735–1743

    Article  PubMed  Google Scholar 

  28. Rogasch JMM, Hundsdoerfer P, Hofheinz F, Wedel F, Schatka I, Amthauer H, Furth C (2018) Pretherapeutic FDG-PET total metabolic tumor volume predicts response to induction therapy in pediatric Hodgkin’s lymphoma. BMC Cancer 18:521

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Eichenauer DA, Plütschow A, Fuchs M, Sasse S, Baues C, Böll B, von Tresckow B, Diehl V, Borchmann P, Engert A (2019) Long-term follow-up of patients with nodular lymphocyte-predominant Hodgkin lymphoma treated in the HD7 to HD15 trials: a report from the German Hodgkin Study Group. J Clin Oncol 38:698–705. https://doi.org/10.1200/JCO.19.00986

    Article  PubMed  Google Scholar 

  30. Andrè MPE, Girinsky T, Federico M et al (2017) Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 35:1786–1794

    Article  PubMed  Google Scholar 

  31. Barrington SF, Philipps EH, Counsell N et al (2019) Positron emission tomography score has greater prognostic significance than pretreatment risk stratification in early-stage Hodgkin lymphoma in the UK RAPID study. J Clin Oncol 37:1732–1741

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nuclear Medicine, University of Brescia and Spedali Civili, Brescia, Italy

    Domenico Albano, Angelica Mazzoletti, Raffaele Giubbini & Francesco Bertagna

  2. Nuclear Medicine, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

    Marianna Spallino & Claudio Rossetti

  3. Haematology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

    Cristina Muzi & Vittorio Ruggiero Zilioli

  4. Division of Hematology, Spedali Civili, Brescia, Italy

    Chiara Pagani & Alessandra Tucci

Authors
  1. Domenico Albano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Angelica Mazzoletti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marianna Spallino
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cristina Muzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vittorio Ruggiero Zilioli
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chiara Pagani
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Alessandra Tucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Claudio Rossetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Raffaele Giubbini
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Francesco Bertagna
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Domenico Albano.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Albano, D., Mazzoletti, A., Spallino, M. et al. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in elderly HL: a two-center experience in 123 patients. Ann Hematol 99, 1321–1330 (2020). https://doi.org/10.1007/s00277-020-04039-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-020-04039-w

Keywords

Search

Navigation